• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Insiders Buying Greenwich LifeSciences And 2 Other Stocks

    3/25/24 9:00:01 AM ET
    $BRT
    $GLSI
    $HROW
    Real Estate Investment Trusts
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BRT alert in real time by email

    Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    Harrow

    • The Trade: Harrow, Inc. (NASDAQ:HROW) 10% owner Opaleye Management Inc. acquired a total of 50,600 shares an average price of $9.65. To acquire these shares, it cost around $488,290.
    • What’s Happening: On March 19, Harrow reported worse-than-expected fourth-quarter financial results.
    • What Harrow Does: Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market.

    Greenwich LifeSciences

    • The Trade: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO and CFO Snehal Patel acquired a total of 1,500 shares at an average price of $17.68. To acquire these shares, it cost around $26,520.
    • What’s Happening: On March 12, Greenwich LifeSciences announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain.
    • What Greenwich LifeSciences Does: Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.

    Don’t forget to check out our premarket coverage here

    BRT Apartments

    • The Trade: BRT Apartments Corp. (NYSE:BRT) 10% owner Gould Investors L P bought a total of 3,471shares at an average price of $16.26. To acquire these shares, it cost around $56,450.
    • What’s Happening: On March 12, BRT Apartments posted downbeat quarterly sales.
    • What BRT Apartments Does: BRT Apartments Corp is a real estate investment trust company. The company is primarily focused on the ownership, operation, and development of multi-family properties.

     

    Check This Out: Top 5 Consumer Stocks That May Crash This Month

    Get the next $BRT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRT
    $GLSI
    $HROW

    CompanyDatePrice TargetRatingAnalyst
    Greenwich LifeSciences Inc.
    $GLSI
    8/20/2025$45.00Outperform
    Noble Capital Markets
    Harrow Inc.
    $HROW
    7/11/2025$76.00Overweight
    Cantor Fitzgerald
    Harrow Inc.
    $HROW
    6/12/2025$62.00Buy
    BTIG Research
    Harrow Inc.
    $HROW
    6/10/2025Outperform
    William Blair
    BRT Apartments Corp. (MD)
    $BRT
    3/13/2025Buy → Neutral
    Colliers Securities
    Harrow Inc.
    $HROW
    2/6/2025$57.00Buy
    H.C. Wainwright
    Harrow Inc.
    $HROW
    12/4/2024$73.00 → $69.00Buy
    B. Riley Securities
    BRT Apartments Corp. (MD)
    $BRT
    4/11/2024$19.50Buy
    B. Riley Securities
    More analyst ratings

    $BRT
    $GLSI
    $HROW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

    NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the "Offering") of $50.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subject to certain exceptions. The Offering is

    3/24/26 4:57:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

    NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer, subject to market and certain other conditions, an additional $50.0 million in aggregate principal amount of its 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subjec

    3/24/26 8:15:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

    STAFFORD, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of new clinical sites in the US. The Phase III clinical trial has recently been activated at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States – specifically at its network sites in Los Angeles and Orange counties, Arizona, Atlanta, and Illinois. Principal investigator at City of Hop

    3/19/26 6:00:00 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRT
    $GLSI
    $HROW
    SEC Filings

    View All

    Harrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - HARROW, INC. (0001360214) (Filer)

    3/27/26 4:05:13 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Harrow Inc.

    SCHEDULE 13G/A - HARROW, INC. (0001360214) (Subject)

    3/27/26 9:34:55 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - HARROW, INC. (0001360214) (Filer)

    3/24/26 4:58:32 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRT
    $GLSI
    $HROW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BRT
    $GLSI
    $HROW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BRT
    $GLSI
    $HROW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CEO and CFO Patel Snehal bought $53,694 worth of shares (1,800 units at $29.83), increasing direct ownership by 0.03% to 5,604,102 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    1/15/26 6:05:06 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and CFO Patel Snehal bought $79,866 worth of shares (2,900 units at $27.54), increasing direct ownership by 0.05% to 5,602,302 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    1/14/26 6:05:06 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and CFO Patel Snehal bought $91,848 worth of shares (4,300 units at $21.36), increasing direct ownership by 0.08% to 5,599,402 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    1/5/26 6:06:39 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. sold $7,846,426 worth of shares (198,572 units at $39.51) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    3/5/26 4:05:14 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. sold $270,900 worth of shares (5,000 units at $54.18) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    3/3/26 4:05:17 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CHIEF COMMERCIAL OFFICER Sullivan Patrick William

    4 - HARROW, INC. (0001360214) (Issuer)

    2/2/26 8:21:48 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Noble Capital Markets initiated coverage on Greenwich LifeSciences with a new price target

    Noble Capital Markets initiated coverage of Greenwich LifeSciences with a rating of Outperform and set a new price target of $45.00

    8/20/25 9:27:20 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Harrow with a new price target

    Cantor Fitzgerald initiated coverage of Harrow with a rating of Overweight and set a new price target of $76.00

    7/11/25 8:12:59 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Harrow with a new price target

    BTIG Research initiated coverage of Harrow with a rating of Buy and set a new price target of $62.00

    6/12/25 7:54:43 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRT
    $GLSI
    $HROW
    Leadership Updates

    Live Leadership Updates

    View All

    BRT Apartments Corp. Declares Third Quarter 2025 Dividend and Announces Management Appointments

    GREAT NECK, New York, Sept. 11, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE:BRT) announced today that its Board of Directors declared a quarterly dividend of $0.25 per share. The dividend is payable October 6, 2025, to stockholders of record at the close of business on September 24, 2025. Additionally, the Company announces the appointment of Matthew Gibbons and Isaac Kalish as chief accounting officer and chief financial officer, respectively. Mr. Gibbons' appointment is effective immediately, and Mr. Kalish's appointment is effective upon the retirement of BRT's current Chief Financial Officer, George Zweier, which the Company anticipates will take place in the first quarter of

    9/11/25 4:10:00 PM ET
    $BRT
    Real Estate Investment Trusts
    Real Estate

    Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. "We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I a

    6/18/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P

    1/7/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRT
    $GLSI
    $HROW
    Financials

    Live finance-specific insights

    View All

    BRT Apartments Corp. Declares First Quarter 2026 Dividend and Announces Increase to Current Stock Repurchase Program

    GREAT NECK, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE:BRT) announced today that its Board of Directors declared a quarterly dividend of $0.25 per share. The dividend is payable April 6, 2026, to stockholders of record at the close of business on March 27, 2026. The Board of Directors also announced that it approved the extension of the Company's share repurchase program through December 31, 2028, and increased the value of the shares to be repurchased to $10 million. BRT is a real estate investment trust that owns, operates and, to a lesser extent, holds interests in joint ventures that own multi-family properties. As of March 11, 2026, BRT owns or has interests

    3/11/26 4:15:00 PM ET
    $BRT
    Real Estate Investment Trusts
    Real Estate

    Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

    Fourth Quarter, Full-Year 2025 and Selected Highlights:  Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year periodFull-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024GAAP net income of $6.6 million in Q4 2025, and net loss $5.1 million for 2025Adjusted EBITDA of $24.2 million in Q4 2025, and $61.9 million for 2025Generated $43.9 million of operating cash flow in 2025, versus $(22.2) million used in operations in 2024Cash and cash equivalents of $72.9 million as of December 31, 2025Full-year 2026 revenue guidance of $350 million to $365 million, including $133 million to $153 million in the first half of

    3/2/26 4:05:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

    NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Monday, March 2, 2026, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, March 3, 2026, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on

    2/18/26 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRT
    $GLSI
    $HROW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    12/5/24 7:08:52 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    10/8/24 6:41:41 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harrow Inc. (Amendment)

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    2/13/24 5:25:53 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care